Nls pharmaceutics announces israeli patent grant covering mazindol for treatment of attention deficit hyperactivity disorder and other sleep disorders through 2037

Israeli patent relates to mazindol use in attention deficit hyperactivity disorder (adhd) or related arousal deficits (i.e., uncontrollable sleepiness), use in the treatment of reduced alertness (daytime sleepiness), or excessive daytime sleepiness, such as narcolepsy or idiopathic hypersomnia.
NLSP Ratings Summary
NLSP Quant Ranking